Olympiad Research LP Takes Position in Personalis, Inc. (NASDAQ:PSNL)

Olympiad Research LP purchased a new position in shares of Personalis, Inc. (NASDAQ:PSNL) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,284 shares of the company’s stock, valued at approximately $59,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. ARK Investment Management LLC lifted its position in Personalis by 11.4% in the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after buying an additional 723,637 shares in the last quarter. abrdn plc purchased a new stake in shares of Personalis during the fourth quarter worth $1,722,000. Walleye Capital LLC acquired a new stake in Personalis during the third quarter valued at $897,000. Jane Street Group LLC increased its position in Personalis by 154.3% in the 3rd quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock worth $884,000 after purchasing an additional 99,671 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Personalis by 20.0% in the 3rd quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock worth $2,683,000 after purchasing an additional 83,068 shares during the last quarter. 61.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $7.25 price target on shares of Personalis in a research note on Wednesday, January 8th. HC Wainwright decreased their target price on shares of Personalis from $11.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, January 27th. Finally, Lake Street Capital increased their price target on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th.

Personalis Stock Performance

Shares of NASDAQ PSNL opened at $4.57 on Tuesday. The business’s 50-day simple moving average is $5.42 and its 200-day simple moving average is $5.04. Personalis, Inc. has a 52 week low of $1.13 and a 52 week high of $7.20. The firm has a market cap of $322.86 million, a price-to-earnings ratio of -2.72 and a beta of 1.73.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.